The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Open accessAbstract
Genetic and epigenetic changes in DNA are involved in cancer development and tumor progression. Histone deacetylases (HDACs) are key regulators of gene expression that act as transcriptional repressors by removing acetyl groups from histones. HDACs are dysregulated in many cancers, making them a therapeutic target for the treatment of cancer. Histone deacetylase inhibitors (HDACi), a novel class of small-molecular therapeutics, are now approved by the Food and Drug Administration as anticancer agents. While they have shown great promise, resistance to HDACi is often observed and furthermore, HDACi have shown limited success in treating solid tumors. The combination of HDACi with standard chemotherapeutic drugs has demonstrated promising anticancer effects in both preclinical and clinical studies. In this review, we summarize the research thus far on HDACi in combination therapy, with other anticancer agents and their translation into preclinical and clinical studies. We additionally highlight the side effects associated with HDACi in cancer therapy and discuss potential biomarkers to either select or predict a patient's response to these agents, in order to limit the off-target toxicity associated with HDACi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Chen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedProteasome inhibitors in glioblastoma
Huang, W., Chen, W.-W., & Zhang, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.5585 · Cited by 8
RetractedHershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“Although cisplatin treatment results in many cases as an initial therapeutic success, chemoresistance eventually develops particularly in non-germ cell solid tumors (25, 75, 76).”
BackgroundSharma, S., Kelly, T. K., & Jones, P. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp220 · Cited by 2,637
DNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
Finley, D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081507.101607 · Cited by 1,764
Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses
Rothkamm, K., & Löbrich, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830918100 · Cited by 1,645 · cited 10×
“To this day, radiotherapy continues to be among the most widely used cancer treatments, causing cell death by the induction of DSBs. HDACi enhance the radiosensitivity of cancer cells (56, 57).”
BackgroundInfluentialHistone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,495
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
The role of histone deacetylases (HDACs) in human cancer
Ropero, S., & Esteller, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.001 · Cited by 997
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
THE GENETIC DEFECT IN ATAXIA-TELANGIECTASIA
Lavin, M. F., & Shiloh, Y. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.177 · Cited by 643
Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 593
Bonneterre, J., Buzdar, A., Nabholtz, J.-M. A., Robertson, J. F. R., Th�rlimann, B., von Euler, M., Sahmoud, T., Webster, A., Steinberg, M., & Arimidex Writing Committee on behalf of the Investigators Committee Members (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y · Cited by 574
Cellular Responses to Cisplatin‐Induced DNA Damage
Basu, A., & Krishnamurthy, S. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/201367 · Cited by 569
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., & Kohn, K. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207515 · Cited by 560
Kim, G., Ison, G., McKee, A. E., Zhang, H., Tang, S., Gwise, T., Sridhara, R., Lee, E., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 528
Weichert, W., Röske, A., Gekeler, V, Beckers, T., Stephan, C., Jung, K., Fritzsche, F. R., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 477
Gore, S. D., Baylin, S., Sugar, E., Carraway, H., Miller, C. B., Carducci, M., Grever, M., Galm, O., Dauses, T., Karp, J. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0080 · Cited by 474
Garcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W. G., Ravandi, F., Koller, C., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009142 · Cited by 467
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454
LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D. S., Goloubeva, O. G., Pien, C. S., Adams, J., et al. (2002) · PubMed · Cited by 450
The role of the redox protein thioredoxin in cell growth and cancer
Powis, G., Mustacich, D., & Coon, A. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00313-0 · Cited by 443
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Cisplatin (cis-diamminedichloroplatinum II)
Prestayko, A. W., D'Aoust, J. C., Issell, B. F., & Crooke, S. T. (1979) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(79)80057-2 · Cited by 405
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Histone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Pei, X.-Y., Dai, Y., & Grant, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0561 · Cited by 382
Error‐Prone Repair of DNA Double‐Strand Breaks
Rodgers, K., & McVey, M. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25053 · Cited by 373
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
New Mechanistic and Functional Insights into DNA Topoisomerases
Chen, S. H., Chan, N.-L., & Hsieh, T.-S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061809-100002 · Cited by 369
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy
Goldberg, A. L. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350012 · Cited by 367
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
Lee, J.-H., Choy, M. L., Ngo, L., Foster, S. S., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008522107 · Cited by 363
Weichert, W., Röske, A., Gekeler, V., Beckers, T., Ebert, M. P., Pross, M., Dietel, M., Denkert, C., & Röcken, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70004-4 · Cited by 360
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Catley, L., Weisberg, E., Kiziltepe, T., Tai, Y.-T., Hideshima, T., Neri, P., Tassone, P., Atadja, P., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 336
Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., & Iwase, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6001-1 · Cited by 305
Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition
Suraweera, A., Münch, C., Hanssum, A., & Bertolotti, A. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.08.003 · Cited by 302
Self-citationConcise Drug Review: Azacitidine and Decitabine
Derissen, E. J. B., Beijnen, J. H., & Schellens, J. H. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0465 · Cited by 299
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Grant, C., Rahman, F., Piekarz, R., Peer, C., Frye, R., Robey, R. W., Gardner, E. R., Figg, W. D., & Bates, S. E. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.88 · Cited by 291
Fu, M., Rao, M., Bouras, T., Wang, C., Wu, K., Zhang, X., Li, Z., Yao, T.-P., & Pestell, R. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500403200 · Cited by 276
Gregory, C. W., Hamil, K. G., Kim, D., Hall, S. H., Pretlow, T. G., Mohler, J. L., & French, F. S. (1998) · PubMed · Cited by 275
Ramalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
Saleh-Gohari, N. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh703 · Cited by 270
Hideshima, T., Richardson, P. G., & Anderson, K. C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0433 · Cited by 265
Preclinical studies identifying carboplatin as a viable cisplatin alternative
Harrap, K. R. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90015-5 · Cited by 259
ATM, a central controller of cellular responses to DNA damage
Khanna, K., Lavin, M., Jackson, S., & Mulhern, T. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400874 · Cited by 252
Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer
Thurn, K. T., Thomas, S., Moore, A., & Munster, P. N. (2011) · Future Oncology · doi:10.2217/fon.11.2 · Cited by 246
Targeting histone deacetylase in cancer therapy
Lin, H., Chen, C., Lin, S., Weng, J., & Chen, C. (2006) · Medicinal Research Reviews · doi:10.1002/med.20056 · Cited by 241
Shah, M. H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M., Farra, Y., Young, D., & Grever, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2689 · Cited by 241
Luu, T. H., Morgan, R. J., Leong, L., Lim, D., McNamara, M., Portnow, J., Frankel, P., Smith, D. D., Doroshow, J. H., Gandara, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0122 · Cited by 237
Bortezomib (Velcade?) in the treatment of multiple myeloma
Field-Smith, A., Morgan, G. J., & Davies, F. E. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.3.271 · Cited by 235
Münster, P., Marchion, D., Bicaku, E., Schmitt, M., Lee, J. H., DeConti, R., Simon, G., Fishman, M., Minton, S., Garrett, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6165 · Cited by 216
Optimizing Combination Chemotherapy by Controlling Drug Ratios
Mayer, L. D., & Janoff, A. S. (2007) · Molecular Interventions · doi:10.1124/mi.7.4.8 · Cited by 214
Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation Proteins
Marchion, D. C., Bicaku, E., Daud, A. I., Sullivan, D. M., & Munster, P. N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2478 · Cited by 212
Kortuem, K. M., & Stewart, A. K. (2013) · Blood · doi:10.1182/blood-2012-10-459883 · Cited by 200
Ramalingam, S. S., Parise, R. A., Ramananthan, R. K., Lagattuta, T. F., Musguire, L. A., Stoller, R. G., Potter, D. M., Argiris, A. E., Zwiebel, J. A., Egorin, M. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0162 · Cited by 193
Richardson, P., Mitsiades, C., Colson, K., Reilly, E., McBride, L., Chiao, J., Sun, L., Ricker, J., Rizvi, S., Oerth, C., et al. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190701817258 · Cited by 190
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. L., & Cloos, J. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.001 · Cited by 189
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
Groselj, B., Sharma, N. L., Hamdy, F. C., Kerr, M., & Kiltie, A. E. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.21 · Cited by 184
Marchion, D. C., Bicaku, E., Daud, A. I., Richon, V., Sullivan, D. M., & Munster, P. N. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20045 · Cited by 184
Molife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., Riggs, C. E., Higano, C., Stadler, W. M., McCulloch, W., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp270 · Cited by 184
Weichert, W., Denkert, C., Noske, A., Darb-Esfahani, S., Dietel, M., Kalloger, S. E., Huntsman, D. G., & Köbel, M. (2008) · Neoplasia · doi:10.1593/neo.08474 · Cited by 180
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
Mithraprabhu, S., Kalff, A., Chow, A., Khong, T., & Spencer, A. (2014) · Epigenetics · doi:10.4161/15592294.2014.983367 · Cited by 175
Fantin, V. R., Loboda, A., Paweletz, C. P., Hendrickson, R. C., Pierce, J. W., Roth, J. A., Li, L., Gooden, F., Korenchuk, S., Hou, X. S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6091 · Cited by 170
Histone-Deacetylase Inhibitors for the Treatment of Cancer
Lindemann, R. K., Gabrielli, B. G., & Johnstone, R. W. (2004) · Cell Cycle · doi:10.4161/cc.3.6.927 · Cited by 168
Munster, P. N., Marchion, D., Thomas, S., Egorin, M., Minton, S., Springett, G., Lee, J.-H., Simon, G., Chiappori, A., Sullivan, D., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605293 · Cited by 167
Epigenetic regulation in cancer progression
Baxter, E., Windloch, K., Gannon, F., & Lee, J. S. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-45 · Cited by 164
Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid
Yang, H., Hoshino, K., Sanchez-Gonzalez, B., Kantarjian, H., & Garcia-Manero, G. (2005) · Leukemia Research · doi:10.1016/j.leukres.2004.11.022 · Cited by 163
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Mazzone, R., Zwergel, C., Mai, A., & Valente, S. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0358-y · Cited by 160
Ocio, E. M., Vilanova, D., Atadja, P. W., Maiso, P., Crusoé, E. D. Q., Fernández‐Lázaro, D., Garayoa, M., San‐Segundo, L., Hernández‐Iglesias, T., de Álava, E., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.015495 · Cited by 159
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
Spiegel, S., Milstien, S., & Grant, S. (2011) · Oncogene · doi:10.1038/onc.2011.267 · Cited by 159
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Takeuchi, K., & Ito, F. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1774 · Cited by 159
Anticancer metal drugs and immunogenic cell death
Terenzi, A., Pirker, C., Keppler, B. K., & Berger, W. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.06.021 · Cited by 151
Münster, P. N., Marchion, D. C., Biçaku, E., Lacevic, M., Kim, J., Centeno, B. A., DAUD, A. I., Neuger, A. M., Minton, S. E., & Sullivan, D. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1930 · Cited by 150
Bradley, D., Rathkopf, D. E., Dunn, R. L., Stadler, W. M., Liu, G., Smith, D. C., Пили, Р., Zwiebel, J. A., Scher, H. I., & Hussain, M. (2009) · Cancer · doi:10.1002/cncr.24597 · Cited by 148
HDAC inhibitors enhance the immunotherapy response of melanoma cells
Booth, L. A., Roberts, J. L., Poklepovic, A. S., Kirkwood, J. M., & Dent, P. (2017) · Oncotarget · doi:10.18632/oncotarget.17950 · Cited by 146
Minamiya, Y., Ono, T., Saito, H., Takahashi, N., Ito, M., Mitsui, M., Motoyama, S., & Ogawa, J. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.019 · Cited by 138
Jekimovs, C., Bolderson, E., Suraweera, A., Adams, M. N., O'Byrne, K. J., & Richard, D. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00086 · Cited by 138
Self-citationPrince, H. M., Bishton, M. J., & Johnstone, R. W. (2009) · Future Oncology · doi:10.2217/fon.09.36 · Cited by 138
Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance
Robey, R. W., Chakraborty, A. R., Basseville, A., Luchenko, V. L., Bahr, J. C., Zhan, Z., & Bates, S. E. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200329f · Cited by 135
Niesvizky, R., Ely, S. A., Mark, T. M., Aggarwal, S., Gabrilove, J. L., Wright, J. J., Chen‐Kiang, S., & Sparano, J. A. (2010) · Cancer · doi:10.1002/cncr.25584 · Cited by 133
Histone deacetylase inhibitors and genomic instability
Éot-Houllier, G., Fulcrand, G., Magnaghi-Jaulin, L., & Jaulin, C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.005 · Cited by 132
Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review
Sawas, A., Radeski, D., & O’Connor, O. A. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715592567 · Cited by 128
Histone deacetylase inhibitors in cancer therapy
Lee, M.-J., Kim, Y. S., Kummar, S., Giaccone, G., & Trepel, J. B. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283127095 · Cited by 128
Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications
Fantin, V. R., & Richon, V. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2114 · Cited by 127
Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
Zhang, G., Park, M. A., Mitchell, C., Hamed, H. A., Rahmani, M., Martin, A. P., Curiel, D. T., Yacoub, A., Graf, M. R., Lee, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0469 · Cited by 118
Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
Thurn, K. T., Thomas, S., Raha, P., Qureshi, I., & Münster, P. N. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1242 · Cited by 115
Rathkopf, D. E., Wong, B. Y., Ross, R. W., Anand, A., Tanaka, E., Woo, M. M., Hu, J. R., Dzik-Jurasz, A., Yang, W., & Scher, H. I. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1289-x · Cited by 111
Sensing of Ionizing Radiation-induced DNA Damage by ATM through Interaction with Histone Deacetylase
Kim, G. D., Choi, Y. H., Dimtchev, A., Jeong, S. J., Dritschilo, A., & Jung, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.44.31127 · Cited by 111
Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer
Diyabalanage, H. V. K., Granda, M. L., & Hooker, J. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.018 · Cited by 111
Gameiro, S. R., Malamas, A. S., Tsang, K. Y., Ferrone, S., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.7180 · Cited by 111
Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinoma
Venturelli, S., Armeanu, S., Pathil, A., Hsieh, C., Weiß, T. S., Vonthein, R., Wehrmann, M., Gregor, M., Lauer, U. M., & Bitzer, M. (2007) · Cancer · doi:10.1002/cncr.22652 · Cited by 110
Rudek, M. A., Zhao, M., He, P., Hartke, C., Gilbert, J., Gore, S. D., Carducci, M. A., & Baker, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.450 · Cited by 109
Marrocco, D. L., Tilley, W. D., Bianco‐Miotto, T., Evdokiou, A., Scher, H. I., Rifkind, R. A., Marks, P. A., Richon, V. M., & Butler, L. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0144 · Cited by 109
Das, C. M., Aguilera, D. G., Vasquez, H., Prasad, P., Zhang, M., Wolff, J. E. A., & Gopalakrishnan, V. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9402-7 · Cited by 102
Miyanaga, A., Gemma, A., Noro, R., Kataoka, K., Matsuda, K., 奈良, 道., Okano, T., Seike, M., Yoshimura, A., Kawakami, A., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2140 · Cited by 102
Increased expression of peroxiredoxin II confers resistance to cisplatin.
Chung, Y. M., Yoo, Y. D., Park, J. K., Kim, Y. T., & Kim, H. J. (2001) · PubMed · Cited by 98
Novel cytotoxic drugs: Old challenges, new solutions
Ismael, G., Rosa, D. D., Mano, M. S., & Awada, A. H. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.08.001 · Cited by 98
Пили, Р., Quinn, D. I., Hammers, H. J., Monk, P., George, S., Dorff, T. B., Olencki, T. E., Shen, L., Orillion, A. R., Lamonica, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1178 · Cited by 97
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
Cao, K., Wang, G., Li, W., Zhang, L., Wang, R., Huang, Y., Du, L., Jiang, J., Wu, C., He, X., et al. (2015) · Oncogene · doi:10.1038/onc.2015.46 · Cited by 95
Modulation of cellular radiation responses by histone deacetylase inhibitors
Karagiannis, T. C., & El‐Osta, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209417 · Cited by 91
Lassen, U., Molife, L. R., Mau‐Sørensen, M., Engelholm, S. A., Vidal, L., Sinha, R., Penson, R. T., Buhl-Jensen, P., Crowley, E. M., Tjørnelund, J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605726 · Cited by 89
Halsall, J. A., & Turner, B. M. (2016) · BioEssays · doi:10.1002/bies.201600070 · Cited by 87
Shabason, J. E., Tofilon, P. J., & Camphausen, K. A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01296.x · Cited by 85
Shen, J., Huang, C., Jiang, L., Gao, F., Wang, Z., Zhang, Y., Bai, J., Zhou, H., & Chen, Q. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.009 · Cited by 85
Nolan, L., Johnson, P., Ganesan, A., Packham, G., & Crabb, S. J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604557 · Cited by 85
Non-Hodgkin Lymphoma Secondary to Cancer Chemotherapy
Krishnan, B., & Morgan, G. J. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-1069 · Cited by 84
Lopez, G., Liu, J., Ren, W., Wei, W., Wang, S., Lahat, G., Zhu, Q.-S., Bornmann, W. G., McConkey, D. J., Pollock, R. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2714 · Cited by 82
DNA Methylation: Its Role in Cancer Development and Therapy
Kurkjian, C. D., Kummar, S., & Murgo, A. J. (2008) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2008.08.002 · Cited by 80
Valentini, A., Gravina, P., Federici, G., & Bernardini, S. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.2.3578 · Cited by 77
Tomita, Y., Lee, M.-J., Lee, S., Tomita, S., Chumsri, S., Cruickshank, S., Ordentlich, P., & Trepel, J. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1219008 · Cited by 75
Björkman, M. L., Iljin, K., Halonen, P., Sara, H., Kaivanto, E., Nees, M., & Kallioniemi, O. (2008) · International Journal of Cancer · doi:10.1002/ijc.23885 · Cited by 73
Romano, E., & Romero, P. J. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0059-z · Cited by 73
Kaushik, D., Vashistha, V., Isharwal, S., Sediqe, S. A., & Lin, M. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215597637 · Cited by 72
Moore, D. C. (2016) · PubMed Central · Cited by 67
Histone Deacetylase Inhibitors as Immunomodulators in Cancer Therapeutics
Shen, L., Orillion, A. R., & Пили, Р. (2016) · Epigenomics · doi:10.2217/epi.15.118 · Cited by 66
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
Marchion, D. C., Biçaku, E., Turner, J. G., Schmitt, M. L., Morelli, D., & Münster, P. N. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0985 · Cited by 65
Hui, K. F., & Chiang, A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28924 · Cited by 60
Buglio, D., Mamidipudi, V., Khaskhely, N. M., Brady, H., Heise, C. C., Besterman, J. M., Martell, R. E., MacBeth, K. J., & Younes, A. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08342.x · Cited by 59
Marchion, D. C., Biçaku, E., Turner, J. G., DAUD, A. I., Sullivan, D. M., & Münster, P. N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1073 · Cited by 55
Noguchi, H., Yamashita, H., Murakami, T., HIRAI, K., NOGUCHI, Y., MARUTA, J., Yokoi, T., & Noguchi, S. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-016 · Cited by 53
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
Campbell, R. A., Sanchez, E., Steinberg, J. A., Shalitin, D., Li, Z., Chen, H., & Berenson, J. R. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01384.x · Cited by 52
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities
Roberts, K. E., Culleton, V., Lwin, Z., O'Byrne, K. J., & Hughes, B. G. M. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12698 · Cited by 46
Self-citationDejligbjerg, M., Grauslund, M., Litman, T., Collins, L. S., Qian, X., Jeffers, M., Lichenstein, H. S., Jensen, P., & Sehested, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-70 · Cited by 45
Yoon, C. Y., Park, M. J., Lee, J. S., et al. (2011) · The Journal of Urology · doi:10.1016/j.juro.2010.10.034 · Cited by 44
Witta, S. E., Dziadziuszko, R., Yoshida, K., Hedman, K., Varella‐Garcia, M., Bunn, P. A., & Hirsch, F. R. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn703 · Cited by 44
Trial watch – inhibiting PARP enzymes for anticancer therapy
Sistigu, A., Manic, G., Obrist, F., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1053594 · Cited by 26
An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer
Pfeiffer, M. J., Mulders, P., & Schalken, J. A. (2010) · The Prostate · doi:10.1002/pros.21187 · Cited by 20
Decatris, M. P., & O'Byrne, K. J. (2016) · Future Oncology · doi:10.2217/fon-2016-0086 · Cited by 8
Self-citationFinding the place of histone deacetylase inhibitors in prostate cancer therapy
Marrocco, D. L., Centenera, M. M., Scher, H. I., Tilley, W. D., & Butler, L. M. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.44 · Cited by 5
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
The great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Xiang, Y., Guo, Z., Zhu, P., Chen, J., & Huang, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2108 · Cited by 752
Metadata
- Authors
- Suraweera, A., O’Byrne, K. J., & Richard, D. J.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-29
- Volume
- 8
- Pages
- 92-92
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2795208162
- Cited by
- 669
- References
- 148
- FWCI
- 27.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.